CoChat

Combined evaluation of LC3B puncta and HMGB1 expression predicts residual risk of relapse after adjuvant chemotherapy in breast cancer

Open access
Ladoire, Sylvain, Penault-Llorca, Frédérique, Senovilla, Laura, Dalban, Cécile, Enot, David, Locher, Clara, Prada, Nicole, Poirier-Colame, Vichnou, Chaba, Kariman, Arnould, Laurent, Ghiringhelli, François, Fumoleau, Pierre, Spielmann, Marc, Delaloge, Suzette, Poillot, Marie Laure, Arveux, Patrick, Goubar, Aicha, Andre, Fabrice, Zitvogel, Laurence, Kroemer, Guido · 2015 · Autophagy
Cited by 113

The DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.

Abstract

In spite of adjuvant chemotherapy, a significant fraction of patients with localized breast cancer (BC) relapse after optimal treatment. We determined the occurrence of cytoplasmic MAP1LC3B/LC3B (microtubule-associated protein 1 light chain 3B)-positive puncta, as well as the presence of nuclear HMGB1 (high mobility group box 1) in cancer cells within surgical BC specimens by immunohistochemistry, first in a test cohort (152 patients) and then in a validation cohort of localized BC patients who all received adjuvant anthracycline-based chemotherapy (1646 patients). Cytoplasmic LC3B(+) puncta inversely correlated with the intensity of SQSTM1 staining, suggesting that a high percentage cells of LC3B(+) puncta reflects increased autophagic flux. After setting optimal thresholds in the test cohort, cytoplasmic LC3B(+) puncta and nuclear HMGB1 were scored as positive in 27.2% and 28.6% of the tumors, respectively, in the validation cohort, while 8.7% were considered as double positive. LC3B(+) puncta or HMGB1 expression alone did not constitute independent prognostic factors for metastasis-free survival (MFS) in multivariate analyses. However, the combined positivity for LC3B(+) puncta and nuclear HMGB1 constituted an independent prognostic factor significantly associated with prolonged MFS (hazard ratio: 0.49 95% confidence interval [0.26-0.89]; P = 0.02), and improved breast cancer specific survival (hazard ratio: 0.21 95% confidence interval [0.05-0.85]; P = 0.029). Subgroup analyses revealed that within patients with poor-prognosis BC, HMGB1(+) LC3B(+) double-positive tumors had a better prognosis than BC that lacked one or both of these markers. Altogether, these results suggest that the combined positivity for LC3B(+) puncta and nuclear HMGB1 is a positive predictor for longer BC survival.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1080/15548627.2015.1082022

Cites

13 of 13 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 13 references

Cited by

See all 113

Metadata

Authors
Ladoire, S., Penault-Llorca, F., Senovilla, L., Dalban, C., Enot, D., Locher, C., Prada, N., Poirier-Colame, V., Chaba, K., Arnould, L., Ghiringhelli, F., Fumoleau, P., Spielmann, M., Delaloge, S., Poillot, M. L., Arveux, P., Goubar, A., Andre, F., Zitvogel, L., & Kroemer, G.
Venue
Autophagy
Published
2015-10-03
Volume
11
Issue
10
Pages
1878-1890
ISSN
  • 1554-8627 (ISSN-L)
  • 1554-8635
OpenAlex
W1889406201
Cited by
113
References
13
FWCI
5.30
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Combined evaluation of LC3B puncta and HMGB1 expression predicts residual risk of relapse after adjuvant chemotherapy in breast cancer. https://app.cochat.ai/papers/10.1080/15548627.2015.1082022
The paper
Ladoire, S., Penault-Llorca, F., Senovilla, L., Dalban, C., Enot, D., Locher, C., Prada, N., Poirier-Colame, V., Chaba, K., Arnould, L., Ghiringhelli, F., Fumoleau, P., Spielmann, M., Delaloge, S., Poillot, M. L., Arveux, P., Goubar, A., Andre, F., Zitvogel, L., & Kroemer, G. (2015). Combined evaluation of LC3B puncta and HMGB1 expression predicts residual risk of relapse after adjuvant chemotherapy in breast cancer. Autophagy. https://doi.org/10.1080/15548627.2015.1082022

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.